Press Release
Akebia Announces Successful Completion of Phase 2a Pilot Study of AKB-6548 For Anemia
Akebia Announces Successful Completion of Phase 2a Pilot Study of AKB-6548 For Anemia
May 3, 2011 at 12:00 AM EDT
Print Page
Email Page
Contact IR
Email Alerts
Tear Sheet
Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142
+1 617.871.2098 phone
+1 617.871.2099 fax